This double-blind, randomised, placebo-controlled, crossover mechanistic trial (n=52) tested single IV infusions of ketamine (0.71 mg/kg), midazolam (0.025 mg/kg), dexmedetomidine (0.025 mg/kg), or saline in non-treatment-seeking smokers.
This randomized, double-blind, crossover study delivers single intravenous infusions of ketamine, midazolam, dexmedetomidine, or saline at least two weeks apart to assess effects on cigarette smoking behaviour, craving, withdrawal and neural measures.
Participants complete 7-day ecological momentary assessment (EMA) periods before and after each infusion, abstain for 24 hours post-infusion with next-day MRI and behavioural assessments, and are closely monitored for physical and subjective adverse effects.
Single IV ketamine infusion (0.71 mg/kg).
Single IV midazolam infusion (0.025 mg/kg).
Midazolam 0.025 mg/kg
Single IV dexmedetomidine infusion (0.025 mg/kg).
Dexmedetomidine 0.025 mg/kg
Single IV saline infusion (placebo).
Normal saline placebo